In an 85-year-old patient with dementia and nighttime agitation who is at high fall risk, what medication can replace aripiprazole to reduce agitation and promote sleep?

Prioritize Non-Pharmacological Interventions First—Medication Should Be Last Resort

Before replacing aripiprazole with another medication, you must first implement and document the failure of non-pharmacological interventions, as antipsychotics carry significant mortality risk in elderly dementia patients and should only be used when agitation is severe, dangerous, or causes significant distress 1.

Critical Context: Why Aripiprazole Should Be Discontinued

Aripiprazole is not FDA-approved for dementia-related agitation and carries a black box warning for increased mortality in elderly patients with dementia-related psychosis 2. Additionally, it increases risk of cerebrovascular events (stroke, TIA) and causes excessive somnolence—particularly dangerous in your 85-year-old patient already at high fall risk 2.

Step 1: Assess and Address Reversible Causes

Before any medication change 1:

• Pain assessment (uncontrolled pain is a common agitation trigger)
• Medication review (polypharmacy, anticholinergics, benzodiazepines)
• Infection screening (UTI, pneumonia)
• Environmental triggers (noise, lighting, overstimulation at night)
• Sleep hygiene (daytime activity, light exposure, consistent bedtime routine)

Step 2: Non-Pharmacological Interventions (Mandatory First-Line)

The APA guidelines require documentation of non-pharmacological intervention attempts before antipsychotic use 1:

• Structured daily activities and exercise
• Music therapy or calming activities before bedtime
• Reduced environmental stimulation at night
• Consistent caregiver approach
• Addressing unmet needs (toileting, hunger, thirst)

Step 3: If Pharmacological Treatment Is Necessary

First-Line Pharmacological Option: Citalopram

For nighttime agitation with sleep promotion needs, citalopram 10-20 mg daily is the safest evidence-based option 3, 4. However, recent meta-analysis shows modest efficacy 5.

Key considerations:

• Start 10 mg daily, may increase to 20 mg (maximum 20 mg in elderly due to QT prolongation risk)
• Monitor QTc interval before initiation and after dose changes
• Takes 2-4 weeks for effect
• Increased fall risk (RR 1.78) 5—critical concern in your high-fall-risk patient
• Better safety profile than antipsychotics for mortality risk

Alternative: Trazodone 25-50 mg at Bedtime

For nighttime agitation specifically targeting sleep, trazodone is a reasonable option 3:

• Start 25 mg at bedtime, titrate to 50-100 mg as needed
• Addresses both agitation and insomnia
• Caution: Orthostatic hypotension and fall risk—particularly problematic in your patient
• Less evidence than citalopram for agitation, but commonly used in practice

If Severe Agitation Requires Antipsychotic (Last Resort)

Only if agitation is severe, dangerous, or causing significant distress AND non-pharmacological interventions have failed 1:

Brexpiprazole 2-3 mg daily is the only FDA-approved medication for agitation in Alzheimer's dementia (approved May 2023) 6, 7, 8:

• Start 0.5 mg daily, titrate slowly over weeks to 2-3 mg
• Takes 6-12 weeks to separate from placebo—requires bridging strategy 8
• Better safety profile than risperidone/aripiprazole
• Small effect sizes but most evidence-based antipsychotic option
• Still carries mortality risk—requires informed consent discussion

Alternative antipsychotics (off-label, higher risk):

• Risperidone 0.25-1 mg daily: Most evidence but highest cerebrovascular risk 7
• Quetiapine 12.5-50 mg at bedtime: Less evidence, sedating, may help sleep 3

Critical Safety Algorithm

For your 85-year-old high-fall-risk patient:

1. Avoid all antipsychotics if possible due to mortality, stroke, and fall risk
2. If medication needed:
   • Best option: Trazodone 25 mg at bedtime (targets nighttime agitation + sleep)
   • Alternative: Citalopram 10 mg daily (if daytime agitation also present)
3. Monitor closely: Falls, orthostasis, QTc (if citalopram), cognitive worsening
4. Reassess at 4 weeks: If no response, taper and discontinue 1
5. If successful: Attempt taper after 3-6 months of stability

Common Pitfalls to Avoid

• Never switch directly to another antipsychotic without attempting non-pharmacological interventions first
• Do not use benzodiazepines—associated with dementia progression and falls 9
• Avoid ramelteon—insufficient evidence for agitation, high withdrawal rates in elderly 9
• Do not continue ineffective medications—reassess at 4 weeks and discontinue if no benefit 1

The safest approach: Maximize non-pharmacological interventions, address pain/sleep hygiene, and use trazodone 25 mg at bedtime if medication is absolutely necessary for nighttime agitation in this high-fall-risk patient.